Olopatadine nasal spray for the treatment of allergicrhinitis

Expert Review of Clinical Immunology

Volumn 6, Issue 2, 2010, Pages 197-204

  Roland, Peter S ^a   Marple, Bradleyf ^a   Wall, G Michael ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Allergic rhinitis; Allergic rhinosinusitis; Antihistamine; Mast cell stabilizer; Nasal spray; Olopatadine hydrochloride; Patanase

Indexed keywords

ASTEPRO; AZELASTINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; OLOPATADINE; PATADAY; PATANASE; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; BITTER TASTE; CLINICAL TRIAL; COUGHING; CREATINE KINASE BLOOD LEVEL; DAILY LIFE ACTIVITY; DESENSITIZATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; HEADACHE; HUMAN; IMMUNOTHERAPY; INFLUENZA; NOSE SEPTUM PERFORATION; PHARYNX DISEASE; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SORE THROAT; THROAT IRRITATION; TREATMENT INDICATION; URINARY TRACT INFECTION; WORK CAPACITY; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, INTRANASAL; CLINICAL TRIALS AS TOPIC; DIBENZOXEPINS; DRUG APPROVAL; EPISTAXIS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; NASAL OBSTRUCTION; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL;

EID: 77949468044     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.89     Document Type: Review

References (34)

1. Settipane RA. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc. 24, 147-154 (2003).
2. Wright AL, Holberg CJ, Martinez FD et al. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 94, 895-901 (1994).
3. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J. Allergy Clin. Immunol. 108(Suppl. 1), S2-S8 (2001).
4. Kishiyama JL. Disorders of the immune system. In: Lange Pathophysiology of Disease. McPhee SJ, Ganong WF (Eds). McGraw-Hill, NY, USA (2005).
5. Clark RR, Baroody FM. What drives the symptoms of allergic rhinitis? J. Respir. Dis. 19, S6-S15 (1998).
6. Krouse JH. Allergic rhinitis - current pharmacotherapy. Otolaryngol. Clin. North Am. 41(2), 347-358 (2008).
7. Krouse JH. The unified airway - conceptual framework. Otolaryngol. Clin. North Am. 41(2), 357-366 (2008).
8. Bousquet J, Van Cauwenberge P, Khaltaev N et al. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108(5 Suppl., Pt 2), S147-S334 (2001).
9. Bosquet J, Khaltaev N. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases. A Comprehensive Approach. Global Alliance against Chronic Respiratory Diseases, WHO, Geneva, Switzerland (2007).
10. International Rhinitis Management Working Group. International Consensus Report on Diagnosis and Management of Rhinitis. Allergy 49(19 Suppl.), 1-34 (1994).
11. Van-Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. EAACI position paper. Allergy 55, 116-134 (2000).
12. Price D, Bond C, Bouchard J et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim. Care Resp. J. 15(1), 58-70 (2006).
13. Wallace DV, Dykewicz MS, Bernsetin DI et al. The diagnosis and management of rhinitis: an updated practice parameter. J. Allergy Clin. Immunol. 122(2 Suppl.), S1-S84 (2008).
14. Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergy/ antihistimic agent. J. Ocular Pharmacol. Ther. 12(4), 256-267 (1996).
15. Sharif NA, Xu SU, Miller ST et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J. Pharmacol. Exp. Ther. 278(3), 1252-1261 (1996).
16. Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J. Pharmacol. 88, 379-397 (2002).
17. Miyake K, Horikoshi K, Ikeda Y et al. Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Jpn J. Pharmacol. 85, 453-456 (2001).
18. Patel D, Garadi R, Brubaker M et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc. 28, 592-599 (2007).
19. Meltzer EO, Hampel F, Ratner P et al. Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 95, 600-606 (2005).
20. Ratner PH, Hampel FC, Amar NJ et al. Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (mountain cedar) allergic rhinitis. Ann. Allergy Asthma Immunol. 95, 474-479 (2005).
21. Fairchild CJ, Meltzer EO, Roland PS et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 28(6), 1-7 (2007).
22. Kaliner MA, Storms W, Tilles S et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. Allergy Astha. Proc. 30(3), 255-262 (2009).
23. Waddell AN, Patel SK, Toma AG, Maw AR. Intransal seteroid sprays in the treatment of rhinitis: is one better than another? J. Laryngol. Otol. 117, 843-845 (2003).
24. Koepke JW, Beaucher WN, Kobayashi RH et al. Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Allergy Ashma Proc.18, 33-37 (1997).
25. VERAMYST® nasal spray prescribing information. GlaxoSmithKline, NC, USA (2007).
26. Meltzer EO, Garadi R, Laforce C et al. Comparitive study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc. 29(6), 659-668 (2008).
27. Lanier BO, Abelson MG, Berger WE et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin. Ther. 24(7), 1161-1174 (2002).
28. Esch RE. Sublingual immunotherapy. Curr. Opin. Otolaryngol. Head Neck Surg. 16(3), 260-264 (2008).
29. Nagai H, Teramachi H, Tuchiya T. Recent advances in the development of anti-allergic drugs. Allergol. Int. 55(1), 35-42 (2006).
30. Passalacqua G, Ciprandi G. Novel therapeutic interventions for allergic rhinitis. Expert Opin. Investig. Drugs 15(12), 1615-1625 (2006).
31. Bohle B, Kinaciayan T, Gerstmayr M et al. Sublingual immunotherapy induces IL-10 producing T regulatory cells, allergen specific T-cell tolerance, and immune deviation. J. Allergy Asthma Immunol. 120, 707-713 (2007).
32. Pajno GB. Sublingual immunotherapy: the optimism and the issues. J. Allergy Clin. Immunol. 119(4), 796-801 (2007).
33. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed- Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355(14), 1445-1455 (2006).
34. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T Cells. J. Allergy Clin. Immunol. 123(4), 735-746 (2009).